AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06630520 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Periarticular injection
Description: A 50ml periarticular injection was introduced intraoperatively before the time of closing. The injection contained 150mg bupivacaine (3mg/mL), 60mg ketorolac(1.2mg/mL) and 1mg morphine.~Before wound closure, periarticular cocktail was injected around the knee joint including the adductor canal from the hamstring harvest side in PAI group. All patients had oral paracetamol 500mg, 4 times/day and diclofenac 75mg, 1 times/day after surgery.
Study NCT06629194 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: interferon gamma releasing assay (IGRA)
Description: All patients who suspected CD or TB will be tested for interferon-gamma releasing assay. An interferon-gamma release assay is a blood test that measures the body\&#39;s immune response to Mycobacterium tuberculosis, the bacteria that causes tuberculosis.
Study NCT06629636 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NMN capsule
Description: Total of 900mg/day for 8 weeks
Study NCT06629636 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NMN-free placebo capsules for 8 weeks
Study NCT06629909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secretome
Description: 3 ml Injection of secretome for 8 times two weeks apart
Study NCT06629337 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: H1 receptor blockade: 540 mg (Allegra), H2 receptor blockade: 40 mg (Pepcid AC)
Description: Subjects ingested fexofenadine (540 mg, tablet) at least 50 minutes before and famotidine (40 mg, tablet) 1 hour 50 minutes before the onset of each protocol because these dose of oral fexofenadine and famotidine reaches its peak concentration at around 1 h and 2 h, respectively
Study NCT06629337 — intervention group
Intervention type: GENETIC
Group type: SHAM_COMPARATOR
Intervention: H1 receptor blockade: 540 mg (Allegra), H2 receptor blockade: 40 mg (Pepcid AC)
Description: Subjects ingested fexofenadine (540 mg, tablet) at least 50 minutes before and famotidine (40 mg, tablet) 1 hour 50 minutes before the onset of each protocol because these dose of oral fexofenadine and famotidine reaches its peak concentration at around 1 h and 2 h, respectively
Study NCT06628583 — intervention group
Intervention type: OTHER
Intervention: Magnetic Resonance Imaging with Contrast
Description: The study was retrospective and did not set interventions
Study NCT06631014 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Early Rehab
Description: The first group of 25 Patients was fitted with Prosthesis with in 6months of duration after amputation.
Study NCT06631014 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Rehab
Description: The 2nd group of 25 patients that was fitted with Prosthesis after the time period of 6months after amputation. No physical rehab was done during this time period including physiotherapy and prosthetic treatment. Main aim was to check the significant impact of delayed rehabilitation.
Study NCT06631898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SaaTwae Bio-Natural Moisturizing Cream
Description: A 0.04 gm of test products along with controls (negative and positive) will be applied on the back of subjects i.e. between the scapula and waist through Finn chamber patch.
Study NCT05784688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TU2218 + Pembrolizumab
Description: TU2218: Orally administered Pembrolizumab: Intravenously administered
Study NCT06713200 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High intensity percutaneous electrolysis
Description: A sterile, disposable stainless steel needle of different lengths depending on the area to be treated will be connected to the EP device; the gauge of these needles will be 0.25 mm. A current of 3 mA will be applied for 3 times with a duration of 3 seconds each. In order to avoid biases, the technique will be performed for 90 seconds as in the low intensity treatment group and in the last 20 seconds the current will be applied with the parameters previously described. Three sessions divided in three consecutive weeks will be applied.
Study NCT06713200 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity Percutaneous Electrolysis
Description: This technique will be performed with the same instrument as the high intensity technique. It differs from the previous treatment group in that the current intensity in this case will be of an amperage of 0.3mA during 90 seconds. In the same way, 3 sessions divided in 21 consecutive days will be applied.
Study NCT06713200 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Simulated Percutaneous Electrolysis
Description: The needle and PD device will be connected in the same way as for the other treatment groups. The needle will be inserted without reaching the lesion area and the characteristic sound of turning on the PD machine will be made. It will last 90 seconds and at no time the galvanic current will be applied. The same aseptic precautions will be applied, in addition to performing the same final hemostasis guidelines and providing the same post-treatment guidelines as for all the other subjects in the study.
Study NCT05946824 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Daily-adaptive Stereotactic Body Radiation Therapy
Description: Daily-adaptive radiation therapy to two dose levels - one to the area of radiologic recurrent nodal disease, and a lower, prophylactic dose to the standard post-prostatectomy and larger pelvic node fields
Study NCT05946824 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Daily-adaptive Stereotactic Body Radiation Therapy
Description: Daily-adaptive radiation therapy to two areas - a high dose to the area of radiologic recurrence, and a lower, prophylactic dose to the standard post-prostatectomy fields
Study NCT03306615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronidase
Description: HYLENEX recombinant, diluted with 0.9% Sodium Chloride Injection
Study NCT03306615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride Injection
Study NCT06157853 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Microneedling
Description: A fractional bipolar radiofrequency microneedling device will be performed at Visit 2, after the 7-day washout period. Subjects were numbed 45 minutes prior to RF microneedling with topical numbing Benzocaine 20%/Lidocaine 6%/tetracaine 4%. Bony areas, periorbital, forehead, and chin were treated with 15 watts at a 2 mm needle depth on cycle mode. All subjects received 20 watts at 3 mm depth on cycle mode on soft tissue, neck, and cheeks.
Study NCT06157853 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radiofrequency Microneedling
Description: A fractional bipolar radiofrequency microneedling device will be performed at Visit 2, after the 7-day washout period. Subjects were numbed 45 minutes prior to RF microneedling with topical numbing Benzocaine 20%/Lidocaine 6%/tetracaine 4%. Bony areas, periorbital, forehead, and chin were treated with 15 watts at a 2 mm needle depth on cycle mode. All subjects received 20 watts at 3 mm depth on cycle mode on soft tissue, neck, and cheeks.
Study NCT06157853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facial Cleanser
Description: Facial cleanser to be used by subjects twice-daily. This product was used during the entire 14-day study (7-day washout period and 7-day post-procedure timeline).
Study NCT06157853 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Facial Cleanser
Description: Facial cleanser to be used by subjects twice-daily. This product was used during the entire 14-day study (7-day washout period and 7-day post-procedure timeline).
Study NCT06157853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facial Moisturizer
Description: Bland moisturizer to be used by subjects twice daily during the 7-day washout period. Use 1 to 2 pumps and place all over face and avoid the eye area.
Study NCT06157853 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Facial Moisturizer
Description: Bland moisturizer to be used by subjects twice daily during the 7-day washout period. Use 1 to 2 pumps and place all over face and avoid the eye area.
Study NCT06157853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen
Description: Bland sunscreen to be used by subjects after cleansing and the facial moisturizer during the 7-day washout period. Bland sunscreen to be used by subjects after cleansing and after the active post-procedure cream and comparator anhydrous cream. Use the provided sunscreen and reapply as needed throughout the day and per recommendation of the FDA, every 2 hours.
Study NCT05139160 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein quality
Description: the present investigation aims to study a novel protein based protein isolate blend with and without leucine an compared with whey protein isolate to determine its impact aminoacidemia and muscle protein synthesis healthy adults.
Study NCT05822895 — intervention group
Intervention type: DEVICE
Intervention: CADe enabled programme (GI Genius)
Description: CADe enabled programme (GI Genius)
Study NCT05625386 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: TMS was performed using a Magstim Rapid2 transcranial magnetic stimulator (Magstim Company, Whitland, UK) with a 70-mm air-cooled figure-of-eight coil. All stimulations were guided by a frameless neuronavigation system (Brainsight; Rogue Research, Montreal, QC, Canada).
Study NCT05625386 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: TMS was performed using a Magstim Rapid2 transcranial magnetic stimulator (Magstim Company, Whitland, UK) with a 70-mm air-cooled figure-of-eight coil. All stimulations were guided by a frameless neuronavigation system (Brainsight; Rogue Research, Montreal, QC, Canada).
Study NCT06553612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary assessment
Description: Delivery of a personalized post-cancer plan with multidisciplinary assessment of oncology support care needs in a day hospital
Study NCT06553612 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard assesment
Description: Delivery of a personalized post-cancer plan without a day hospital
Study NCT06553612 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observational cohort
Description: Patients with no cancer sequelae, no adverse effects and no need for oncological support care will not be randomized, but will be followed as part of an observational cohort
Study NCT06307665 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BDA MDI
Description: Participants will receive oral inhalation of BDA MDI 160/180 μg taken as 2 puffs of 80/90 μg as needed.
Study NCT06307665 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: AS MDI
Description: Participants will receive oral inhalation of AS MDI 180 μg taken as 2 puffs of 90 μg as needed.
Study NCT05624749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ianalumab
Description: ianalumab s.c. monthly
Study NCT05624749 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo s.c. monthly
Study NCT05605743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: breathing exercise
Description: Thirty hypertensive geriatric with high tension type primary open angle glaucoma will perform breathing exercise (alternate nostril breathing). The daily breathing exercise will be performed by the geriatrics in evening (for half an hour) and morning (for half an hour) for one month.
Study NCT04878042 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide
Description: Mouth wash and nasal spray 3 times a day for 3 days
Study NCT04878042 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mouth wash and nasal spray 3 times a day for 3 days
Study NCT05520827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1584862
Description: BI 1584862
Study NCT05520827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04902586 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TTFields
Description: The TTFields, consisting of low-intensity, 200 kHz frequency, alternating electric fields, was delivered (≥ 18 hours/d) via 4 transducer arrays on the shaved scalp and connected to a portable device.
Study NCT06631612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferric hydroxide polymaltose complex
Description: participants will receive oral iron supplementation according to body weight every other day
Study NCT06631612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ferric hydroxide polymaltose complex
Description: participants will receive oral iron supplementation dose according to body weight daily
Study NCT06631612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole.
Description: both arms will receive Albendazole 400mg once at the beginning f the study to be repeated after 1 week
Study NCT06631612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole.
Description: both arms will receive Albendazole 400mg once at the beginning f the study to be repeated after 1 week
Study NCT05058664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A-F texting component
Description: Over the course of the 6-week intervention parents in the A-F condition will receive 1 message each day.
Study NCT05058664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: P-F texting component
Description: Over the course of the 6 week intervention, parents will receive between 1-2 messages, depending on randomization (in addition to A-F component messages)
Study NCT05516901 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The erector spinae plane block group
Description: The probe should then slowly be moved laterally until the transverse process is visible. The 100 mm, 25-gauge needle should be inserted using an in-plane approach in the cephalad to caudal direction and advanced under ultrasound guidance towards the transverse process; once the needle tip is below the erector spinae muscle, a small bolus of local anesthetic should be given. The erector spinae muscle should be visualized, separating from the transverse process. After aspiration the local anesthetic (20 ml of 0.25% bupivacaine was injected. Technique was repeated on the other side.
Study NCT05516901 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Patients in this group will receive general anesthesia alone.
Study NCT06330948 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SugarCut® Unripe Guava Fruit Extract
Description: This trial adopted a double-blind placebo-controlled parallel testing design. Subjects will be randomly assigned to the SugarCut® Guava Extract group. Before the trial (week 0), subjects are required to undergo fasting blood collection and height, weight, and blood pressure examinations. Afterwards, the test samples were given to the subjects for 8 consecutive weeks, and they were reviewed for evaluation at the 4th and 8th weeks, and fasting blood collection and height, weight, and blood pressure examinations were performed.
Study NCT06330948 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: This trial adopted a double-blind placebo-controlled parallel testing design. Subjects will be randomly assigned to the placebo group. Before the trial (week 0), subjects are required to undergo fasting blood collection and height, weight, and blood pressure examinations. Afterwards, the test samples were given to the subjects for 8 consecutive weeks, and they were reviewed for evaluation at the 4th and 8th weeks, and fasting blood collection and height, weight, and blood pressure examinations were performed.
Study NCT06336798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30mg
Description: Study participants will take Pioglitazone 30 mg PO daily
Study NCT06336798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Study participants will take a placebo PO daily
Study NCT05070104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-613
Description: 250-1000mg/m2 -14 day cycle
Study NCT05070104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modified FFX
Description: Irinotecan: 150mg/m2 IV over 90 min-14 day cycle Leucovorin: 400mg/m2 IV over 2hrs with Irinotecan-14 day cycle Oxaliplatin: 85mg/m2 IV over 2hrs-14 day cycle 5FU: 2400mg/m2 IV over 46-48 hrs-14 day cycle
Study NCT05070104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5mg/kg IV
Study NCT05000450 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ALLO-605
Description: ALLO-605 is an anti-BCMA, TRAC/CD52 allogeneic edited, intracellular cytokine signaling containing, CAR T cell product
Study NCT05000450 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLO-647
Description: ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
Study NCT05000450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Chemotherapy for lymphodepletion
Study NCT05000450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy for lymphodepletion
Study NCT05599399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gum acacia
Description: 25 grams of gum acacia powder is administered on daily-basis
Study NCT06009419 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: The control group will receive the usual post-operative care of stretching, lower extremity strengthening, balance exercises, activities of daily living recommendations. The study group will be given a dual task program in addition to the program given to the control group.
Study NCT06009419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: The control group will receive the usual post-operative care of stretching, lower extremity strengthening, balance exercises, activities of daily living recommendations. The study group will be given a dual task program in addition to the program given to the control group.
Study NCT06431035 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: caffeine
Description: The participants chewed either caffeine gum (5 mg/kg for 10 minutes per chew) or a placebo (10 minutes per chew, using regular gum).
Study NCT06431035 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: caffeine
Description: The participants chewed either caffeine gum (5 mg/kg for 10 minutes per chew) or a placebo (10 minutes per chew, using regular gum).
Study NCT04338165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab 140 MG/ML [Repatha]
Description: 3 injections of evolocumab 140 milligrams performed within 30 minutes and self-administered (subcutaneously in the abdomen, thigh, or upper arm)
Study NCT05085184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of UI018
Description: Test
Study NCT05085184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: co-administration of UIC201806 and UIC201602
Description: Reference
Study NCT06421948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linperlisib and chidamide
Description: A combination of linperlisib and chidamide will be administered for 6 cycles in patients responded to treatment.
Study NCT06421948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone
Description: A combination of cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone (CHOP) will be administered for 6 cycles in patients responded to treatment.
Study NCT04456920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phone consultation
Description: At D1, D2 and D3, patients in the experimental group 1 will receive a call from a neuro-psychologist during which pain, anxiety and esthetical biopsy impact will be assessed using numeric or visual analog scales during a semi-direct interview. During this call, any adverse events related to the breast biopsy will also be noted, as well as the amount, nature and dose of analgesics, anxiolytics, anti-depressants, anti-inflammatory and hypnotics taken linked to the biopsy. If detected, pain or significative distress would be specifically managed.
Study NCT04456920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-PRO self-completed via connected objects (tablet/phone)
Description: Patients in the experimental group 2 will be asked by SMS or notification to connect to the application in order to complete online the numeric and visual anog scales of pain, anxiety and esthetical impact. Any adverse events related to the breast biopsy will also be noted online, as well as the amount, nature and dose of analgesics, anxiolytics, anti-depressants, anti-inflammatory and hypnotics taken for the biopsy. If detected, pain or significative distress would be specifically managed
Study NCT04456920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phone consultation
Description: At D4 post biopsy, all patients (of the 3 groups) will receive a phone call from a neuro-psychologist to assess pain, anxiety and esthetical impact, using numeric scales, and to collect adverse events. If detected, pain or significative distress would be specifically managed.
Study NCT06336798 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Labs
Description: Labs will be performed for Urine HCG, Complete Blood count (CBC), Chemistry Panel, Fasting lipids, insulin, glucose, and Bioenergetic analysis (platelets).